A Herpes Simplex Virus Vector System for Expression of Complex Cellular cDNA Libraries

Wolfe, Darren; Craft, April M.; Cohen, Justus B.

doi:10.1128/jvi.02388-09

Cited by 11 publications

(13 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1B) into the LAT locus (Wolfe et al, 2010) with the 932 bp CGRP and 970 bp NF200 promoter sequences (SwitchGear Genomics, Carlsbad CA), the 553 bp CMV (Thomsen et al, 1984; Stinski and Roehr, 1985), and 1284 bp TRPV1 (Xue et al, 2007; personal communication with Mark Schumacher, UCSF) promoter sequences. The identity of each promoter-mCherry reporter pENTR plasmid was verified by sequence analysis.…”

Section: Methodsmentioning

confidence: 99%

“…The identity of each promoter-mCherry reporter pENTR plasmid was verified by sequence analysis. Isolates of each of the 4 promoter-reporter vectors that were purified by 3 rounds of limiting analysis (Goins et al, 2002) were subjected to FIGE analysis (Wolfe et al, 2010) and sequencing of the inserted cassette into the LAT region to confirm the structure of the 4 vectors (Fig. 1B).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Morphological changes in different populations of bladder afferent neurons detected by herpes simplex virus (HSV) vectors with cell-type-specific promoters in mice with spinal cord injury

et al. 2017

Self Cite

View full text Add to dashboard Cite

Functional and morphological changes in C-fiber bladder afferent pathways are reportedly involved in neurogenic detrusor overactivity (NDO) after spinal cord injury (SCI). This study examined the morphological changes in different populations of bladder afferent neurons after SCI using replication-defective herpes simplex virus (HSV) vectors encoding the mCherry reporter driven by neuronal cell type-specific promoters. Spinal intact (SI) and SCI mice were injected into the bladder wall with HSV mCherry vectors driven by the cytomegalovirus (CMV) promoter, CGRP promoter, TRPV1 promoter or neurofilament 200 (NF200) promoter. Two weeks after vector inoculation into the bladder wall, L1 and L6 dorsal root ganglia (DRG) were removed bilaterally for immunofluorescent staining using anti-mCherry antibody. The number of CMV promoter vector-labeled neurons was not altered after SCI. The number of CGRP and TRPV1 promoter vector-labeled neurons was significantly increased whereas the number of NF200 vector-labeled neurons was decreased in L6 DRG after SCI. The median size of CGRP promoter-labeled C-fiber neurons was increased from 247.0 in SI mice to 271.3 µm2 in SCI mice whereas the median cell size of TRPV1 promoter vector-labeled neurons was decreased from 245.2 in SI mice to 216.5 µm2 in SCI mice. CGRP and TRPV1 mRNA levels of laser-captured bladder afferent neurons labeled with Fast Blue were significantly increased in SCI mice compared to SI mice. Thus, using a novel HSV vector-mediated neuronal labeling technique, we found that SCI induces expansion of the CGRP- and TRPV1-expressing C-fiber cell population, which could contribute to C-fiber afferent hyperexcitability and NDO after SCI.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Morphological changes in different populations of bladder afferent neurons detected by herpes simplex virus (HSV) vectors with cell-type-specific promoters in mice with spinal cord injury

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…The cell divisiondependent, hit-and-run capability of our vectors is expected to be ideal for this purpose. We have also been able to create expression libraries using HSV vectors (Wolfe et al, 2010) that can be used, for example, to identify new reprogramming and transdifferentiation genes. We have recently used an HSV-based cellular cDNA library to discover activities that regulate ion channels and control pain responses in nociceptors (Srinivasan et al, 2007;Reinhart et al, unpublished).…”

Section: The Future Of Hsv Vectorsmentioning

confidence: 99%

Herpes Simplex Viral Vectors: Late Bloomers with Big Potential

Glorioso

2014

Human Gene Therapy

Self Cite

View full text Add to dashboard Cite

“…However, replication could be rescued by expression of a dominant-negative form of TRPV1 from a second HSV vector. This observation holds promise for the use of HSV-based cDNA libraries (Wolfe et al, 2010) to select for genes that negatively regulate TRPV1 or other ion channels involved in pain signaling.…”

Section: Gene Therapy Approaches For the Treatment Of Chronic Painmentioning

confidence: 99%

Gene therapy for the treatment of chronic peripheral nervous system pain

Goins

Cohen

Glorioso

2012

Neurobiology of Disease

Self Cite

View full text Add to dashboard Cite

Chronic pain is a major health concern affecting 80 million Americans at some time in their lives with significant associated morbidity and effects on individual quality of life. Chronic pain can result from a variety of inflammatory and nerve damaging events that include cancer, infectious diseases, autoimmune-related syndromes and surgery. Current pharmacotherapies have not provided an effective long-term solution as they are limited by drug tolerance and potential abuse. These concerns have led to the development and testing of gene therapy approaches to treat chronic pain. The potential efficacy of gene therapy for pain has been reported in numerous pre-clinical studies that demonstrate pain control at the level of the spinal cord. This promise has been recently supported by a Phase-I human trial in which a replication-defective herpes simplex virus (HSV) vector was used to deliver the human pre-proenkephalin (hPPE) gene, encoding the natural opioid peptides met- and leu-enkephalin (ENK), to cancer patients with intractable pain resulting from bone metastases (Fink et al., 2011). The study showed that the therapy was well tolerated and that patients receiving the higher doses of therapeutic vector experienced a substantial reduction in their overall pain scores for up to a month post vector injection. These exciting early clinical results await further patient testing to demonstrate treatment efficacy and will likely pave the way for other gene therapies to treat chronic pain.

show abstract

A Herpes Simplex Virus Vector System for Expression of Complex Cellular cDNA Libraries

Cited by 11 publications

References 24 publications

Morphological changes in different populations of bladder afferent neurons detected by herpes simplex virus (HSV) vectors with cell-type-specific promoters in mice with spinal cord injury

Morphological changes in different populations of bladder afferent neurons detected by herpes simplex virus (HSV) vectors with cell-type-specific promoters in mice with spinal cord injury

Herpes Simplex Viral Vectors: Late Bloomers with Big Potential

Gene therapy for the treatment of chronic peripheral nervous system pain

Contact Info

Product

Resources

About